- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
- Interventions
- Guadecitabine, Treatment Choice
- Drug · Other
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 22
- States / cities
- Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 5,325
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Retinal Vein Occlusion
- Interventions
- ranibizumab, Peripheral Laser
- Drug · Other
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Interventions
- GLP-1 medication
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Weston, Florida • Cleveland, Ohio
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Itacitinib, Extracorporeal Photopheresis (ECP)
- Drug · Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Napabucasin, Paclitaxel
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Santa Rosa, California • Aventura, Florida + 2 more
- Conditions
- Skin Cancer, Metastatic Melanoma
- Interventions
- Aldesleukin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bronchiolitis
- Interventions
- Aerosolized Infasurf
- Combination Product
- Lead sponsor
- ONY
- Industry
- Eligibility
- 0 Months to 4 Months
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Acute Coronary Syndrome
- Interventions
- MT1002 for Injection
- Drug
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Muncie, Indiana
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Adagrasib, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- GNE Myopathy, Hereditary Inclusion Body Myopathy (HIBM)
- Interventions
- SA-ER 500 mg, SA-IR 500 mg
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Los Angeles, California • St Louis, Missouri • New York, New York
- Conditions
- Chronic Lymphocytic Leukemia, CLL
- Interventions
- Revlimid, Rituximab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
- Interventions
- ganetespib, Sirolimus
- Drug
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Iowa City, Iowa + 4 more
- Conditions
- Type 2 Diabetes, Type 2 Diabetes (T2DM)
- Interventions
- Eroxon®, tadalafil
- Device · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Synchronous Gastric Peritoneal Carcinomatosis, Gastroesophageal Peritoneal Carcinomatosis
- Interventions
- Cisplatin, Mitomycin C
- Drug
- Lead sponsor
- Mohammad Haroon Asif Choudry
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Pembrolizumab, Pemetrexed, Oxaliplatin, Dexamethasone, Folic Acid, Vitamin B-12
- Drug · Dietary Supplement
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 15
- States / cities
- Gainesville, Florida • Decatur, Illinois • Effingham, Illinois + 8 more
- Conditions
- Primary Systemic Amyloidosis
- Interventions
- Doxycycline
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Solid Tumor
- Interventions
- Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus
- Drug
- Lead sponsor
- Miller Children's & Women's Hospital Long Beach
- Other
- Eligibility
- 12 Months to 31 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2029
- U.S. locations
- 2
- States / cities
- Long Beach, California • Orange, California
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Deferoxamine, Normal saline
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 10
- States / cities
- Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- oral belinostat
- Drug
- Lead sponsor
- Valerio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York • Houston, Texas
- Conditions
- HIV-1
- Interventions
- D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more
- Conditions
- Advanced Malignancies, Solid Tumor, Hematological Malignancy
- Interventions
- Pelabresib
- Drug
- Lead sponsor
- Constellation Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Gettysburg, Pennsylvania • West Valley City, Utah
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Preterm Birth
- Interventions
- Intervention Arm Weekly IP3 text messages, Active Control Arm General pregnancy text messages
- Behavioral · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina